Innovative Strategy for Resistant Depression and Suicidal Ideation: HEOR Analysis From the Perspective of BRAZIL / LATAM / LMIC .
Author(s)
ELIO TANAKA, Sr., MD1, ELAINE BREGOLA, RESEARCHER2, Helena Maria Romcy, MSc, MD2, Goldete Priszkulnik, MSc, MD2, JOSE MARIO JUNIOR, RESEARCHER2.
1MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 2TNK, CURITIBA PR, Brazil.
1MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 2TNK, CURITIBA PR, Brazil.
OBJECTIVES: We study the chance of a possible decrease in suicide ideation rates, based on scientific data and informations from a promising innovation strategy based on clinical end point.
METHODS: From database of the Notifiable Diseases Information System (SINAN) & Suicide data from the Mortality Information System (SIM) of the year 2022. A total of 496,583 cases of suicide from 2019 to 2022 in Brazilian scenario and a suicide attempt due to exogenous intoxication a subtotal of 4,259 cases, in one specific State (Brazil ). Data from international literature showing a strategy using esketamine intranasal and antidepressant treatment decreased: the risk of relapse by 51% (Hazard Ratio [HR], 0.49; 95% ci, 0.29-0.84) among patients who achieved stable remission, and 70% (HR, 0.30; 95% ci, 0.16-0.55) among those who achieved stable response compared to treatment with antidepressants and placebo.
RESULTS: We speculate that 51% (Hazard Ratio [HR] of 496,583 CASES, means that esketamine and antidepressant treatment decreased the risk of relapse to avoidance risk of suicidal ideation in 253.257 cases. The 2,172 / 4,259 cases of attempted suicide reported in exogenous intoxication data, could contemplate the chances of rescue from “de novo" treatments and better clinical outcomes.
CONCLUSIONS: For patients who have experienced remission or response after treatment with esketamine, there is a chance to resume a new treatment protocol in order to avoid loss of life or loss of productivity in cases of sequelae/suicide attempt. However, lengthy follow-up is needed in order to answer to this, with regard to economic impact and other outcomes.
METHODS: From database of the Notifiable Diseases Information System (SINAN) & Suicide data from the Mortality Information System (SIM) of the year 2022. A total of 496,583 cases of suicide from 2019 to 2022 in Brazilian scenario and a suicide attempt due to exogenous intoxication a subtotal of 4,259 cases, in one specific State (Brazil ). Data from international literature showing a strategy using esketamine intranasal and antidepressant treatment decreased: the risk of relapse by 51% (Hazard Ratio [HR], 0.49; 95% ci, 0.29-0.84) among patients who achieved stable remission, and 70% (HR, 0.30; 95% ci, 0.16-0.55) among those who achieved stable response compared to treatment with antidepressants and placebo.
RESULTS: We speculate that 51% (Hazard Ratio [HR] of 496,583 CASES, means that esketamine and antidepressant treatment decreased the risk of relapse to avoidance risk of suicidal ideation in 253.257 cases. The 2,172 / 4,259 cases of attempted suicide reported in exogenous intoxication data, could contemplate the chances of rescue from “de novo" treatments and better clinical outcomes.
CONCLUSIONS: For patients who have experienced remission or response after treatment with esketamine, there is a chance to resume a new treatment protocol in order to avoid loss of life or loss of productivity in cases of sequelae/suicide attempt. However, lengthy follow-up is needed in order to answer to this, with regard to economic impact and other outcomes.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD32
Topic
Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Mental Health (including addition), SDC: Neurological Disorders, STA: Alternative Medicine